ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/cervical/metastatic
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gynaecological / Cervical - Metastatic
18
trial(s) found.
NCT06910657
Advanced
Phase 1
Not yet recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06581432
Advanced
Phase 2
Recruiting
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours (
1479-0009
)
ERBB2 inhibitor,second generation
Breast cancer
Cervical cancer
Gastroesophageal junction adenocarcinoma
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
Urothelial carcinoma
Uterine serous carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06465069
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors (
NEXUS-01
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06459180
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (
2870-020
)
anti-Trop2 antibody-drug conjugate
Cervical cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate
Bladder cancer
Cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Pancreatic cancer
Platinum resistant ovarian cancer
Sarcoma
Small-cell lung cancer
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06238479
Advanced
Phase 1
Recruiting
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors (
EXCEED
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06172478
Advanced
Phase 2
Recruiting
HERTHENA-PanTumor01 (
U31402-277
): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
anti-ERBB3 antibody-drug conjugate
Bladder cancer
Cervical cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
High-grade serous ovarian cancer
Melanoma
Oesophageal cancer
Pancreatic adenocarcinoma
Prostate adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
NA
4032 - Chermside - ICON Cancer Centre
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT05891171
Advanced
Phase 1
Recruiting
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (
ARC-25
)
anti-CD39 monoclonal antibody
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Gastric cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Triple-negative breast cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
NCT05081609
Advanced
Phase 1 / Phase 2
Recruiting
IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (
IL-Believe
)
TLR7/TLR8 agonist
anti-PD-1 monoclonal antibody
Breast cancer
Cervical cancer
Melanoma
Non-small cell lung cancer
Platinum resistant ovarian cancer
Small-cell lung cancer
Solid tumour
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5065 - Toorak Gardens - Burnside War Memorial Hospital (TERMINATED)
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04644068
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (
PETRA
)
PARP1-selective inhibitor
Biliary tract cancer
Bladder cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Small-cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT04140526
Advanced
Phase 1 / Phase 2
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (
PRESERVE-001
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Adenoid cystic carcinoma
Breast cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Salivary gland cancer
Sarcoma
Small-cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2305 - New Lambton Heights - Newcastle Private Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT03746431
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours (
FPX-01-01
)
FPI-1175
FPI-1547
IGF1R-radionucleotide conjugate
cancer therapy
radioconjugate therapy
radiopharmaceutics
Breast cancer
Carcinoma
Cervical cancer
Endometrial cancer
HER2-negative breast cancer
Head and neck squamous cell carcinoma
Ovarian cancer
Solid tumour
Triple-negative breast cancer
Uveal melanoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
NCT02628067
Advanced
Phase 2
Recruiting
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) (
KEYNOTE-158
)
anti-PD-1 monoclonal antibody
Anal cancer
Biliary tract cancer
Cancer
Cervical cancer
Cholangiocarcinoma
Colorectal cancer
Endometrial cancer
Endometrial carcinoma
Lung carcinoid tumour
Mesothelioma
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Salivary gland cancer
Salivary gland carcinoma
Small-cell lung cancer
Solid tumour
Thyroid cancer
Vulval cancer
NSW
2109 - North Ryde - Macquarie University Hospital
NCT05858736
Advanced
Phase 1
Active not recruiting
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study (
PRESERVE-009
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Adenocarcinoma
Anal cancer
Biliary tract cancer
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Fallopian tube cancer
Gastric cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Primary peritoneal serous carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05500508
Advanced
Phase 1 / Phase 2
Terminated
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer (
AMXT1501-102
)
polyamine transport inhibitor
Breast cancer
Cancer
Central nervous system cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
H3K27M-mutant glioma
Head and neck cancer
Malignant glioma
Melanoma
Mesothelioma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Papillary thyroid cancer
Pleural mesothelioma
Solid tumour
NSW
2145 - Westmead - The Children's Hospital at Westmead
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (15)
Not yet recruiting (1)
Active not recruiting (1)
Terminated (1)
Recruitment Country and State
NSW (12)
QLD (10)
VIC (9)
SA (8)
WA (4)
TAS (1)
Phase
Phase 1 (7)
Phase 1 / Phase 2 (7)
Phase 2 (3)
Phase 3 (1)
Trial Type
Advanced (18)
Cancer Therapy Class
PD-1
39%
PD-1/PD-L1
39%
ERBB2
17%
NECTIN4
11%
Trop2
11%
CTLA4
11%
TF
6%
FR-alpha
6%
VEGF
6%
B7H3
6%
ERBB3
6%
CD39
6%
IL-2
6%
TLR7/TLR8
6%
CCR8
6%
ER
6%
PARP
6%
PARP1-selective
6%
oestrogen axis
6%
polyamine transport
6%
Facility
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
2109 - North Ryde - Macquarie University Hospital (3)
4215 - Southport - Tasman Oncology (3)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
3168 - Clayton - Monash Medical Centre (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
4032 - Chermside - ICON Cancer Centre
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
6009 - Nedlands - One Clinical Research (1)
2305 - New Lambton Heights - Newcastle Private Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
Cancer Type
Cancer
Cervical cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Solid tumour
Viral-related cancer
Thoracic cancer
Gastrointestinal cancer
Lung cancer
Respiratory tract cancer
Upper gastrointestinal cancer
Ovarian cancer
Breast cancer
Gastroesophageal cancer
Head and neck cancer
Non-small cell lung cancer
Pancreatobiliary cancer
Urogenital cancer
Gastric cancer
Oesophageal cancer
Pancreatic cancer
Colorectal cancer
Lower gastrointestinal cancer
Melanoma
Endometrial cancer
Bladder cancer
Head and neck squamous cell carcinoma
Clear cell renal cell carcinoma
Kidney cancer
Male genital cancers
Prostate cancer
Breast adenocarcinoma
Triple-negative breast cancer
Carcinoma
Hepatobiliary cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Epithelial Ovarian Cancer
Hepatocellular carcinoma
Sarcoma
Endometrial carcinoma
Urothelial carcinoma
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Mesothelioma
Biliary tract cancer
Renal pelvis cancer
Platinum resistant ovarian cancer
Prostate adenocarcinoma
Fallopian tube cancer
Peritoneal cancer
Pleural mesothelioma
Primary peritoneal serous carcinoma
Salivary gland cancer
Anal cancer
Endocrine gland cancer
Thyroid cancer
Uterine serous carcinoma
Castrate-resistant prostate cancer
Acral lentiginous melanoma
Biomarker-defined solid tumour
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
MSI-H/dMMR solid tumour
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Skin cancer
Squamous non-small-cell lung cancer
dMMR solid cancer
Colorectal adenocarcinoma
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Adenoid cystic carcinoma
Cancer Solid tumour Carcinoma
HER2-negative breast cancer
Uveal melanoma
Cholangiocarcinoma
Gastro-entero-pancreatic neuroendocrine tumour
Lung carcinoid tumour
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Salivary gland carcinoma
Vaginal and vulvar cancer
Vulval cancer
Adenocarcinoma
Central nervous system cancer
Differentiated thyroid carcinoma
Glioma
H3K27M-mutant glioma
High-grade glioma
Malignant glioma
Neurological cancer
Papillary thyroid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy